The S&P 500 (SNPINDEX: ^GSPC ) has soared in the past four years, leading many to fear that the index is long overdue for a major correction. In times of trouble, value investors often look to stocks that trade at low valuations compared with their peers to provide a margin of safety from a potential downturn.
Yet judging stocks on a single valuation metric can lead to misleading conclusions that can prove costly. Today, let's take a look at some of the least expensive stocks in the S&P on a price-to-book value basis, with an eye toward understanding why book value might not be the best way to judge whether these stocks are truly cheap.
The cheapest stocks in the S&P
On a book-value basis, financial stocks have had low book values for a long time. Genworth Financial (NYSE: GNW ) trades at just one-third of book value, while plenty of other insurance companies and banks offer price-to-book ratios of between 0.5 and 0.75. Yet during the financial crisis, investors learned just how inaccurate book values were. Massive writedowns of toxic assets proved necessary to reflect the actual value of those assets, and as a result, price-to-book ratios temporarily soared even as stock prices plunged.
Top 5 Bank Stocks To Watch For 2015: Gevo Inc (GEVO)
Gevo, Inc., incorporated in June 2005, is a renewable chemicals and advanced biofuels company. The Company is focused on the development and commercialization of alternatives to petroleum-based products. The Company operates in two segments: Gevo, Inc. Segment and Gevo Development/Agri-Energy Segment. Gevo, Inc. Segment is responsible for all research and development activities related to the future production of isobutanol, maintaining and protecting its intellectual property portfolio, developing future markets for its isobutanol and providing corporate oversight services. Its Gevo Development/Agri-Energy Segment is responsible for the production of ethanol and related products. In September 2010, the Company acquired a 22 MGPY ethanol production facility in Luverne, Minnesota that the Company intends to retrofit to produce isobutanol.
The Company�� isobutanol can also be converted by its customers into a range of hydrocarbons, which form the basis for the production of many products, including plastics, fibers, rubber and other polymers and hydrocarbon fuels, including jet and diesel fuel. Its technology platform consists of biocatalysts and a isobutanol separation unit. Together these technologies form the Gevo Integrated Fermentation Technology (GIFT). GIFT is designed to allow relatively low capital expenditure retrofits of existing ethanol facilities, enabling isobutanol production from a range of renewable feedstocks. The Company�� biocatalysts are microorganisms that have been designed to metabolize sugars to produce isobutanol.
GIFT consists of two components, biocatalysts which convert sugars derived from multiple renewable feedstocks into isobutanol through fermentation, and a separation unit which is designed to continuously separate isobutanol from water during the fermentation process. The Company developed its technology platform to be compatible with the existing approximately 20 BGPY of global operating ethanol production capacity, as estimated by the R! enewable Fuels Association (RFA).
The Company competes with Butamax Advanced Biofuels LLC (Butamax), BP p.l.c. (BP), E. I. du Pont de Nemours and Company, Butalco GmbH, Cathay Industrial Biotech Ltd., METabolic EXplorer S.A., TetraVitae Bioscience, Inc., Cobalt Technologies, Inc., Green Biologics Ltd. Shell Oil Products US (Shell Oil), BP, DuPont-Danisco Cellulosic Ethanol LLC, Abengoa Bioenergy, S.A., POET, LLC, ICM, Mascoma, Range Fuels, Inbicon A/S, INEOS New Planet BioEnergy LLC, Coskata, Archer Daniels Midland Company, BlueFire Ethanol, Inc., KL Energy Corporation, ZeaChem Inc., Iogen Corporation, Qteros, Inc., and AE Biofuels, Inc.
Advisors' Opinion:- [By Robert Rapier]
KiOR (Nasdaq: KIOR) is one of three advanced biofuel companies that venture capitalist Vinod Khosla took public in 2011. The other two were Amyris (Nasdaq: AMRS) and Gevo (Nasdaq: GEVO). Each of these companies has seen its share price drop sharply since the IPO. While KiOR is one of the few companies to have produced advanced biofuel for sale, the volumes have consistently come in below company guidance, and I expect production costs to remain above the sales price for the foreseeable future.
- [By Maxx Chatsko]
I imagine the company has made headway since its initial press release, especially with commissioning for its Moema, Brazil, biorefinery looming. When updates are given on commercial achievements in the months ahead, will you be able to digest the important information that affects your investments? Heading into the homestretch of the first wave of commercial buildout, it is crucially important to understand what Solazyme, Gevo (NASDAQ: GEVO ) , and�Amyris� (NASDAQ: AMRS ) spill in press releases -- and the greater detail given in SEC filings.
- [By Alyce Lomax]
Solazyme is more than a biofuels play like fellow biofuels upstarts like Amyris (NASDAQ: AMRS ) and Gevo (NASDAQ: GEVO ) . I purchased shares of Solazyme for the Prosocial Portfolio (I hold shares in my personal portfolio, too) not only for its impressive foray into a nascent field, but also because it had already inked some impressive partnerships. Meanwhile, its alternative oils go much further than simply trying to provide alternatives to fossil fuels. Its microalgae-derived oils can also be used in skin care and food.
Best Cheapest Stocks To Buy Right Now: Monarch Casino & Resort Inc (MCRI)
Monarch Casino & Resort, Inc. (Monarch), incorporated in 1993, through its wholly owned subsidiary, Golden Road Motor Inn, Inc. (Golden Road), owns and operates the Atlantis Casino Resort Spa(the Atlantis), a hotel/casino facility in Reno, Nevada. Monarch�� other wholly owned subsidiaries, High Desert Sunshine, Inc. (High Desert) and Golden North, Inc. (Golden North), each own separate parcels of land located adjacent to the Atlantis. The Company owns and operates the Atlantis Casino Resort Spa, which is located approximately three miles south of downtown in the area of Reno, Nevada. The Atlantis features approximately 61,000 square feet of casino space; a hotel with 824 guest rooms and suites; ten food outlets; an enclosed year-round pool with waterfall; an outdoor pool; a health spa; two retail outlets offering clothing and resort gift shop merchandise; a full service salon for men and women; an 8,000 square-foot family entertainment center; and approximately 52,000 square feet of banquet, convention and meeting room space. During the year ended December 31, 2011, the Company acquired 1.5 acre parcel of developable land contiguous to the Riviera Black Hawk Casino.
In April 2012, it acquired Riviera Black Hawk, Inc.
The Atlantis Casino offers approximately 1,450 slot and video poker machines; approximately 39 table games, including blackjack, craps, roulette and others; a race and sports book; keno and a poker room. The Atlantis includes three contiguous high-rise hotel towers with 824 rooms and suites. The Atlantis includes three contiguous high-rise hotel towers with a total of 824 rooms and suites. The first of the three hotel towers contains 160 rooms and suites in 13 stories. The 19-story second hotel tower contains 278 rooms and suites. The third tower contains 386 rooms and suites in 28 stories.
The Atlantis hotel rooms feature designs and furnishings consistent with the Northern Nevada market, as well as nine-foot ceilings (most standard hotel rooms have eig! ht-foot ceilings), which create an open and spacious feel. The third hotel tower features a four-story waterfall with an adjacent year-round swimming pool in a climate controlled, five-story glass enclosure, which shares an outdoor third floor pool deck with a seasonal outdoor swimming pool and year round whirlpool. A full-service salon (the Salon at Atlantis) overlooks the third floor sundeck and outdoor seasonal swimming pool and offers salon-grade products and treatments for hair, nails, skincare and body services for both men and women. A health spa is located adjacent to the swimming areas, which offers treatments and amenities. The hotel rooms on the spa floor are designated as spa rooms and feature decor that is themed consistent with the spa. Certain spa treatments are also available in spa floor hotel rooms. The hotel also features glass elevators rising the full 19 and 28 stories, of the respective towers providing views of the Reno area and the Sierra Nevada mountain range.
The Atlantis has eight restaurants, two gourmet coffee bars and one snack bar. It includes 160-seat Atlantis Steakhouse gourmet restaurant; the 200-seat upscale Bistro Napa featuring a centrally located wine cellar; the Oyster Bar restaurant in the Sky Terrace offering fresh seafood, soups and bisques made to order; the Sushi Bar, also in the Sky Terrace, offering a variety of fresh raw and cooked sushi specialties, including all-you-can-eat lunch and dinner selections. The Oyster Bar and Sushi Bar can accommodate up to 139 guests; The 178-seat 24-hour Purple Parrot coffee shop; the 122-seat Cafe Alfresco restaurant serving a full menu, pizzas prepared in a wood-fired, brick oven and a variety of gelato deserts; the 170-seat Manhattan Deli restaurant specializing in piled-high sandwiches, soups, salads and desserts; two gourmet coffee bars, offering specialty coffee drinks, pastries and desserts made fresh daily in the Atlantis bakery; a snack bar and soda fountain serving ice cream and arcade-style refreshmen! ts.
The Sky Terrace is a structure with a diamond-shaped, blue glass body suspended approximately 55 feet, and spanning 160 feet across, South Virginia Street. The Sky Terrace connects the Atlantis with additional parking on its 16-acre site across South Virginia Street from the Atlantis. The structure rests at each end on two 100-foot tall Grecian columns with no intermediate support pillars. The interior of the Sky Terrace contains the Oyster Bar, the Sushi Bar, a video poker bar, banks of slot machines and a lounge area with oversized leather sofas and chairs.
Advisors' Opinion:- [By Ben Levisohn]
Monarch Casino & Resort (MCRI) fell 15% to $18.71 after revenue missed forecasts today.
Stamps.com (STMP) fell 6.2% today ahead of its earnings results. It beat earnings after the close today.
Best Cheapest Stocks To Buy Right Now: Titan Pharmaceuticals Inc (TTNP)
Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.
Probuphine
Probuphine is the first product to utilize the Company�� ProNeura long-term drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.
Iloperidone
Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ilop! eridone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.
Spheramine
Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated with human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.
Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide development, manufacturing and commercialization rights, and, in ad! dition to! the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.
Advisors' Opinion:- [By CRWE]
Today, TTNP surged (+2.76%) up +0.018 at $.689 with 152,996 shares in play thus far (ref. google finance Delayed: 2:02PM EDT October 1, 2013).
Titan Pharmaceuticals, Inc. previously reported that the U.S. Food and Drug Administration (FDA) has granted the request for a meeting to discuss Probuphine庐. The meeting is scheduled for November 19, 2013. The FDA has designated this as a Type C meeting and has requested the submission of briefing materials by October 7, 2013.
Best Cheapest Stocks To Buy Right Now: Pacira Pharmaceuticals Inc.(PCRX)
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, commercialization, and manufacture of pharmaceutical products for use in hospitals and ambulatory surgery centers. The company develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. Its product portfolio includes EXPAREL, a long-acting non-opioid postsurgical analgesic for postsurgical pain management; DepoCyt for the treatment of lymphomatous meningitis, a cancer of the immune system; DepoDur for controlling post operative pain; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate that is in preclinical trials for the treatment of rheumatoid arthritis oncology. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Advisors' Opinion:- [By STOCKPICKR]
Pacira Pharmaceuticals (PCRX) is an emerging specialty pharmaceutical company engaged in development, commercialization and manufacture of proprietary pharmaceutical products for use in hospitals and ambulatory surgery centers. This stock closed up 12.5% at $55.93 in Monday's trading session.
Monday's Volume: 944,000
Three-Month Average Volume: 517,152
Volume % Change: 80%
From a technical perspective, PCRX exploded higher here back above its 50-day moving average of $52.50 with above-average volume. This stock recently formed a double bottom chart pattern at $46.55 to $47.21. Since forming that bottom, shares of PCRX have started to rip higher and move within range of triggering a major breakout trade. That trade will hit if PCRX manages to take out Monday's intraday high of $56 to its 52-week high at $56.94 with high volume.
Traders should now look for long-biased trades in PCRX as long as it's trending above its 50-day at $52.20 and then once it sustains a move or close above those breakout levels with volume that's near or above 517,152 shares. If that breakout hits soon, then PCRX will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $60 to $63.
A.M. Castel
A.M. Castel (CAS) is a specialty metals and plastics distribution company. Its core products include nickel alloys, aluminum, stainless steel and carbon in various forms, such as plate, bars, tubing and coil. This stock closed up 9% at $14.88 in Monday's trading session.
Monday's Volume: 487,000
Three-Month Average Volume: 156,083
Volume % Change: 204%
From a technical perspective, CAS gapped sharply higher here back above its 50-day moving average of $14.27 and into breakout territory above some near-term overhead resistance at $14.37 with strong upside volume. This move pushed shares of CAS out of its downtre
Best Cheapest Stocks To Buy Right Now: Alimera Sciences Inc.(ALIM)
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company is developing ILUVIEN, an intravitreal insert in phase-3 clinical trials for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN insert designed to be inserted into the patient?s eye to release a daily dose of fluocinolone acetonide over an anticipated period of 24 to 36 months. The company also conducts phase-2 clinical trials on ILUVIEN for the treatment of the dry form of age-related macular degeneration (AMD), the wet form of AMD, and retinal vein occlusion. In addition, it conducts testing on two classes of nicotinamide adenine dinucleotide phosphate oxidase inhibitors. Further, the company develops I LUVIEN inserter, a custom insertion system for ILUVIEN. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Advisors' Opinion:- [By Smith On Stocks]
This note focuses on the implications of the complete response letter (CRL) received by Alimera (ALIM) for Iluvien. This product was developed by pSivida (PSDV) but was partnered with Alimera. This report deals only with the investment significance for pSivida.
- [By John Kell]
Specialty pharmaceutical firm pSivida Corp.(PSDV) said the U.S. Food and Drug Administration didn’t approve a treatment for an eye disease found in patients with diabetes. The company’s stock tumbled 47% to $2 premarket, while shares of Alimera Sciences Inc.(ALIM) were down 39% to $1.66, as the treatment is licensed and sold by Alimera in other markets.
Best Cheapest Stocks To Buy Right Now: Avery Dennison Corp (AVY)
Avery Dennison Corporation (Avery Dennison), incorporated on February 23, 1977, is engaged in the production of pressure-sensitive materials, and a variety of tickets, tags, labels other converted products, and office and consumer products through embossing, printing, stamping and die-cutting. The Company operates in two segments: Pressure-sensitive Materials and Retail Branding and Information Solutions. In addition to its reportable segments, the Company has other specialty converting businesses comprised of Vancive Medical Technologies (Vancive) and Designed and Engineered Solutions (DES). Some are sold by the Company in converted form as printable media, tapes and reflective sheeting. The Company also manufacture and sells office and consumer products, other converted products and items not involving pressure-sensitive components, such as binders, organizing systems, markers, fasteners and business forms, as well as tickets, tags, radio-frequency identification (RFID) inlays and tags, and imprinting equipment and related services for retailers and apparel manufacturers. In 2012, the PSM and RBIS segments contributed approximately 71% and 25%, of its total sales, respectively. In 2012, international operations constituted a substantial majority of its business, representing approximately 72% of its sales. As of December 29, 2012, the Company operated approximately 200 manufacturing and distribution facilities worldwide, employed approximately 30,000 persons, and had operations in over 50 countries. In July 2013, Avery Dennison Corp completed the sale of its Office and Consumer Products and Designed and Engineered Solutions businesses to CCL Industries Inc.
Pressure-sensitive Materials Segment
Pressure-sensitive Materials segment manufactures and sells Fasson-,JAC -, and Avery Dennison-brand pressure-sensitive label and packaging materials, Avery- and Avery Dennison-brand graphics and graphic films, Avery Dennison-brand reflective products, and performance polymers (largel! y used to manufacture pressure-sensitive materials). The business of this segment tends not to be seasonal, except for certain outdoor graphics and reflective products and operations in Europe. Pressure-sensitive materials consist primarily of papers, plastic films, metal foils and fabrics, which are coated with company-developed and purchased adhesives, and then laminated with specially coated backing papers and films. They are sold in roll or sheet form with either solid or patterned adhesive coatings, and are available in a wide range of face materials, sizes, thicknesses and adhesive properties. These label and packaging materials are sold worldwide to label printers and converters for labeling, decorating, fastening, electronic data processing and special applications in the home and personal care, beer and beverage, durables, pharmaceutical, wine and spirits, and food market segments. A pressure-sensitive, or self-adhesive, material is one that adheres to a surface by press-on contact.
The Company�� graphics and reflective businesses sell a variety of films and other products to the architectural, commercial sign, digital printing, and other related market segments. The Company also sells durable cast and reflective films to the construction, automotive and fleet transportation market segments; and reflective films for traffic and safety applications. The Company provides sign shops, commercial printers and designers a range of pressure-sensitive materials to enable the creation of impactful and informative, brand and decorative graphics. The Company has an array of pressure-sensitive vinyl and specialty materials designed for digital imaging, screen printing and sign cutting applications.
The Company�� performance tapes business manufactures and sells coated tapes and adhesive transfer tapes for use in non-mechanical fastening, bonding and sealing systems in various industries. These tapes are sold to industrial original equipment manufacturers, converters, and dispo! sable dia! per producers worldwide in roll form and are available in a range of face materials, sizes, thicknesses and adhesive properties. Performance polymer products include a range of solvent- and emulsion-based acrylic polymer adhesives, protective coatings and other polymer additives for internal use, as well as for sale to other companies.
The Company competes with Raflatac, MacTac, Ritrama, Inc., Flexcon Corporation, Inc., Orafol Group, Inc., 3M, Tesa-SE, and Nitto Denko Corporation.
Retail Branding and Information Solutions Segment
The Company�� Retail Branding and Information Solutions segment (RBIS) designs, manufactures and sell a wide variety of branding and information solutions to retailers, brand owners, apparel manufacturers, distributors and industrial customers on a worldwide basis. RBIS branding solutions include creative services, brand embellishments, graphic tickets, tags, and labels, and sustainable packaging. RBIS information solutions include RFID-enabled inventory accuracy, visibility and loss prevention solutions, price ticketing and marking, care and content or origin compliance solutions, and brand protection and security solutions.
The Company competes with SML Group, R-pac Internation Corporation, and Checkpoint Systems.
Other specialty converting businesses
The Company�� specialty converting businesses include its designed and engineered solutions and Vancive businesses. These businesses manufacture and sell specialty tapes, engineered films, pressure-sensitive postage stamps and other converted products. These businesses are generally not seasonal, except for certain automotive products due to plant shutdowns by automotive manufacturers. It�� designed and engineered solutions business manufactures custom pressure-sensitive labels and multi-layer film constructions for durable goods, electronics and consumer packaged goods. These products are sold primarily to original equipment manufacturers, tie! r supplie! rs and packaging converters. For the automotive market segment, the businesses manufactures custom pressure-sensitive and heat-seal labels, and pressure-sensitive films, which are sold primarily to original equipment manufacturers and their suppliers. Its Vancive business manufactures an array of pressure-sensitive adhesive products for surgical, wound care, ostomy, and electromedical applications. These products are sold primarily to medical supply and device manufacturers and healthcare providers.
Advisors' Opinion:- [By Dan Caplinger]
3M has also done a good job of defending its intellectual property. Late last month, the company announced that it had won a lawsuit against Avery Dennison (NYSE: AVY ) for patent infringement, and the court dismissed counterclaims that Avery had filed against 3M.
- [By Marc Bastow]
Pressure-sensitive materials producer Avery Dennison (AVY) raised its quarterly dividend 21% to 35 cents per share payable June 18 to shareholders of record June 4.
AVY Dividend Yield: 2.88%
No comments:
Post a Comment